The Cancer Prevention and Control Program (CPC) organizes and promotes all cancer prevention and control-related research activities in the Winship Cancer Institute (Winship) and across Emory University. The CPC Program capitalizes on being in a research university with schools of medicine and nursing and a full-featured, nationally ranked school of public health from which to build a cancer center program that addresses the full spectrum of cancer prevention and control research. Research within the program is characterized by four scientific themes: 1) Cancer Epidemiology, Biomarkers, and Chemoprevention;2) Health Behavior Research;3) Symptom Management and Control;and 4) Health Outcomes and Quality of Care. These themes address the program's goals of reducing cancer risk, incidence, morbidity, and mortality in Georgia through: describing and tracking cancer incidence and mortality trends of all cancers;conducting population-based etiologic research in humans;conducting chemoprevention trials in Georgia and in national collaborations;conducting research that applies theories of human behavior to prevent cancer through early detection;conducting research to characterize the scope of behavioral co-morbidities which occur in patients with cancer;understanding relevant mechanisms and treatments of these behavioral co-morbidities;and conducting research that describes, interprets, and predicts the impact of interventions and other factors on cancer outcomes important to decision makers. The CPC Program has members from 12 departments across all three schools within Emory University: the Schools of Public Health, Nursing, and Medicine. The program has 31 core members and 12 coalition members (persons in non-affiliated institutions in Atlanta [i.e., the American Cancer Society and the Center for Disease Control and Prevention] who actively participate in the CPC Program's activities), and a portfolio of 42 NIH and other national, peer-reviewed, cancer-related grants headed by 20 core members, with a combined annual funding of $9,763,879 in program direct costs (out of a total of 57 externally-funded cancer research grants with $11,188,786 in program direct costs). The number of peer-reviewed cancer publications by CPC core members during the current grant period was 247, of which 24% were Intraprogrammatic and 14% were inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-06
Application #
8634045
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$26,926
Indirect Cost
$9,656
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Qi, Q; Kang, S S; Zhang, S et al. (2017) Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression. Oncogene 36:4562-4572
Cornely, Ronald M; Schlingmann, Barbara; Shepherd, Whitney S et al. (2017) Two common human CLDN5 alleles encode different open reading frames but produce one protein isoform. Ann N Y Acad Sci 1397:119-129
Lee, Byoungkoo; Konen, Jessica; Wilkinson, Scott et al. (2017) Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics. Sci Rep 7:39498
Zhong, Jim; Patel, Kirtesh; Switchenko, Jeffrey et al. (2017) Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123:3486-3493
Morris, Lydia P; Conley, Andrew B; Degtyareva, Natalya et al. (2017) Genome-wide map of Apn1 binding sites under oxidative stress in Saccharomyces cerevisiae. Yeast 34:447-458
Kim, Yong Joon; Kaluz, Stefan; Mehta, Anil et al. (2017) Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example. Bio Protoc 7:
Cassidy, Richard J; Liu, Yuan; Patel, Kirtesh et al. (2017) Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base. Cancer 123:783-793
Gavile, Catherine M; Barwick, Benjamin G; Newman, Scott et al. (2017) CD86 regulates myeloma cell survival. Blood Adv 1:2307-2319
Ivanov, A A; Gonzalez-Pecchi, V; Khuri, L F et al. (2017) OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene 36:5852-5860
Fei, Baowei; Guolan Lu; Halicek, Martin T et al. (2017) Label-free hyperspectral imaging and quantification methods for surgical margin assessment of tissue specimens of cancer patients. Conf Proc IEEE Eng Med Biol Soc 2017:4041-4045

Showing the most recent 10 out of 265 publications